PANBELA THERAPEUTICS INC (PBLA) Stock Price & Overview
NASDAQ:PBLA • US69833W4042
Current stock price
The current stock price of PBLA is 1.11 USD. Today PBLA is down by -9.76%. In the past month the price decreased by -7.5%. In the past year, price decreased by -99.73%.
PBLA Key Statistics
- Market Cap
- 1.41M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4,010.88
- Dividend Yield
- N/A
PBLA Stock Performance
PBLA Stock Chart
PBLA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PBLA. When comparing the yearly performance of all stocks, PBLA is a bad performer in the overall market: 99.92% of all stocks are doing better.
PBLA Earnings
PBLA Forecast & Estimates
8 analysts have analysed PBLA and the average price target is 418.2 USD. This implies a price increase of 37575.68% is expected in the next year compared to the current price of 1.11.
PBLA Groups
Sector & Classification
PBLA Financial Highlights
Over the last trailing twelve months PBLA reported a non-GAAP Earnings per Share(EPS) of -4010.88. The EPS decreased by -67.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PBLA Ownership
PBLA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.31 | 374.127B | ||
| AMGN | AMGEN INC | 15.58 | 188.572B | ||
| GILD | GILEAD SCIENCES INC | 16.07 | 175.711B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 112.769B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.42 | 81.989B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.06 | 43.4B | ||
| INSM | INSMED INC | N/A | 34.527B | ||
| NTRA | NATERA INC | N/A | 29.881B | ||
| BIIB | BIOGEN INC | 11.02 | 26.402B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.24 | 25.496B | ||
| MRNA | MODERNA INC | N/A | 20.576B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.173B | ||
| INCY | INCYTE CORP | 12.66 | 19.083B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PBLA
Company Profile
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
Company Info
IPO: 2014-07-29
PANBELA THERAPEUTICS INC
712 Vista Blvd # 305
Waconia MINNESOTA 55387 US
CEO: Jennifer K. Simpson
Employees: 6
Phone: 19524791196
PANBELA THERAPEUTICS INC / PBLA FAQ
What does PBLA do?
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 6 full-time employees. The company went IPO on 2014-07-29. The firm is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The firm's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.
What is the stock price of PANBELA THERAPEUTICS INC today?
The current stock price of PBLA is 1.11 USD. The price decreased by -9.76% in the last trading session.
Does PBLA stock pay dividends?
PBLA does not pay a dividend.
How is the ChartMill rating for PANBELA THERAPEUTICS INC?
PBLA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for PANBELA THERAPEUTICS INC?
PANBELA THERAPEUTICS INC (PBLA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for PBLA stock?
PANBELA THERAPEUTICS INC (PBLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4010.88).